3/20
07:10 am
phvs
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology [Yahoo! Finance]
Low
Report
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology [Yahoo! Finance]
3/12
11:12 am
phvs
KalVista Pharmaceuticals: Has Potential But With Caveats [Seeking Alpha]
Low
Report
KalVista Pharmaceuticals: Has Potential But With Caveats [Seeking Alpha]
3/11
06:50 am
phvs
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
Medium
Report
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
3/9
09:56 am
phvs
Pharvaris (PHVS) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $52.00 price target on the stock.
Neutral
Report
Pharvaris (PHVS) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $52.00 price target on the stock.
3/3
12:16 pm
phvs
Pharvaris (PHVS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Pharvaris (PHVS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
3/2
07:09 am
phvs
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 [Yahoo! Finance]
Low
Report
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 [Yahoo! Finance]
3/2
06:50 am
phvs
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
Low
Report
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
2/28
01:30 am
phvs
Low
Report
2/10
07:02 am
phvs
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting [Yahoo! Finance]
Low
Report
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting [Yahoo! Finance]
2/10
06:50 am
phvs
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Low
Report
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
2/7
02:07 am
phvs
Low
Report
1/17
09:48 pm
phvs
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap [Yahoo! Finance]
Medium
Report
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap [Yahoo! Finance]
1/17
01:11 am
phvs
1/12
06:50 am
phvs
Pharvaris Outlines 2026 Strategic Priorities
Low
Report
Pharvaris Outlines 2026 Strategic Priorities
1/3
01:08 am
phvs
Medium
Report